Research / Stocks / GMED GMED NYSE CIK 0001237831
GLOBUS MEDICAL INC · Surgical & Medical Instruments & Apparatus
COVERAGE / STANDARD
Latest filing 4 · Aug 19, 2026
Research state Latest filing analysis is current
Last SEC check Sep 13, 2026
Data basis Official SEC · no quote feed Component status Filing Evidence Research Current Official SEC filing history is available
Structured Financials Research Current Validated structured financial research is available
Filing Analysis Research Current No filing analysis job is currently running
Fundamental State Research Current Fundamental State depends on validated comparable financial metrics
RESEARCH SNAPSHOT GLOBUS MEDICAL INC's latest supported as-filed period reports revenue of $789.6M , 5.9% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
Deterministic / evidence backed Key research observations No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Current configuration / point in time Fundamental state A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Capex intensity 0th Own-history percentile · N=11
Method Level · gp.fundamentals.capex_revenue_ratio
Raw value 4.20% · OPTIONAL
Operating cash generation 64th Own-history percentile · N=11
Method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 26.56% · OPTIONAL
Revenue growth RAW Current state valid · history insufficient
Method Yoy · gp.fundamentals.revenue
Raw value 5.94% · CORE
Inventory pressure 45th Own-history percentile · N=11
Method Level · gp.fundamentals.inventory_revenue_ratio
Raw value 102.70% · OPTIONAL
Operating margin 100th Own-history percentile · N=11
Method Level · gp.fundamentals.operating_margin
Raw value 23.10% · CORE
R&D intensity 0th Own-history percentile · N=11
Method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 4.60% · OPTIONAL
SBC intensity 27th Own-history percentile · N=11
Method Level · gp.fundamentals.sbc_revenue_ratio
Deterministic multi-period research Company direction Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
As filed Jun 30, 2026 General Corporate
Capital Allocation 4 evidence-backed dimensions Capex Intensity Inflecting Cash Generation Improving R And D Intensity Decreasing Sbc Intensity Improving [email protected] · 12 historical states · 38% confidenceCompany Direction 7 evidence-backed dimensions Capex Intensity Inflecting Cash Generation Improving Inventory Pressure Stable Profitability Improving R And D Intensity Decreasing [email protected] · 12 historical states · 36% confidenceFinancial Quality 4 evidence-backed dimensions Cash Generation Improving Inventory Pressure Stable Profitability Improving Sbc Intensity Improving [email protected] · 12 historical states · 38% confidenceGovernance Evidence 4 evidence-backed dimensions Filing Amendments None Detected Auditor Changes None Detected Sbc Intensity Observed Insider Activity Observed [email protected] · 12 historical states · 50% confidenceInterpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Comparable evidence Peer context Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
Inventory Pressure
GMED 102.7
Peer median 72.0
Peer percentile 76th 79 valid peers · 90% coverage · +1.0 robust σ Cash Generation
GMED 26.6
Peer median -10.1
Peer percentile 98th 81 valid peers · 92% coverage · +1.0 robust σ Profitability
GMED 23.1
Peer median -6.7
Peer percentile 95th 83 valid peers · 94% coverage · +0.9 robust σ Sbc Intensity
GMED 1.7
Peer median 5.9
Peer percentile 21th 81 valid peers · 92% coverage · -0.6 robust σ R And D Intensity
GMED 4.6
Peer median 13.2
Peer percentile 22th 68 valid peers · 77% coverage · -0.6 robust σ Capex Intensity
GMED 4.2
Peer median 3.0
Peer percentile 67th 73 valid peers · 83% coverage · +0.4 robust σ Open group breadth → Divergence is context, not positive or negative. INSIDER STATE / 90D Recent disclosed activity
Open-market purchases 0
Sales 0
Distinct buyers 0
Repeat buyer NO Conservative Form 4 classification · not a sentiment label Flagship analysis / V3 What changed? The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q 0001628280-26-054450 9 governed changes · top 7 shown
01
HIGH IMPORTANCE Cash 100TH HISTORICAL PCTL · N=2
Cash & equivalents increased 121.3% Cash & equivalents changed +121.3% from the comparable as-filed period.
Why this ranks here · [email protected] $229.4M → $507.7M Comparable → current
02
LOW IMPORTANCE Inventory 0TH HISTORICAL PCTL · N=4
Inventory increased 5.0% Inventory changed +5.0% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Why this ranks here · [email protected] $772.1M → $810.9M Comparable → current
03
HIGH IMPORTANCE Net Income 33TH HISTORICAL PCTL · N=3
Net income decreased 25.3% Net income changed -25.3% from the comparable as-filed period.
Why this ranks here · [email protected] $202.8M → $151.6M Comparable → current
04
HIGH IMPORTANCE Operating Income 67TH HISTORICAL PCTL · N=3
Operating income increased 139.7% As-filed financials Financial trajectory Each point keeps the date investors could first observe it and its accession.
As filed Current normalized · later
Capex / revenue 4.20% -19.4% ↓ Capital expenditure $33.2M -16.3% ↓ Cash & equivalents $507.7M +0.0% ↑ Free-cash-flow proxy $176.6M +8.5% ↑ Gross margin 58.70% -2.5% ↓ Interest income $7.1M +30.2% ↑ Inventory $810.9M +5.0% ↑ Net income $151.6M +21.9% ↑
ACTIVE TRACE Revenue GMED · as filed with the SEC · reported-date aware
Capex / revenue Q2 / 2026-06-30 4.20% -19.4% sequential point Trace ↗ Evidence inspector
Loading lineage… × Capital expenditure Q2 / 2026-06-30 $33.2M -16.3% sequential point Trace ↗ Evidence inspector
Loading lineage… × Cash & equivalents Q2 / 2026-06-30 $507.7M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Free-cash-flow proxy Q2 / 2026-06-30 $176.6M +8.5% sequential point Trace ↗ Evidence inspector
Loading lineage… × Gross margin Q2 / 2024-06-30 58.70% -2.5% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest income Q2 / 2026-06-30 $7.1M +30.2% sequential point Trace ↗ Evidence inspector
Loading lineage… × Inventory Q2 / 2026-06-30 $810.9M +5.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Net income Q2 / 2026-06-30 $151.6M +21.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating cash flow Q2 / 2026-06-30 $209.7M +3.6% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating margin Q2 / 2026-06-30 23.10% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Research & development Q2 / 2026-06-30 $36.3M -0.5% sequential point Trace ↗ Evidence inspector
Loading lineage… × Revenue Q2 / 2026-06-30 $789.6M +3.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Primary evidence Filing timeline Direct SEC links, filing dates, report periods, and amendment flags.
4 Aug 19, 2026 Period Aug 18, 2026 0001193125-26-357121SEC ↗ 10-Q Aug 6, 2026 Period Jun 30, 2026 0001628280-26-054450SEC ↗ 8-K Aug 6, 2026 Period Aug 6, 2026 0001628280-26-054353SEC ↗ 4 Jul 28, 2026 Period Jul 27, 2026 0001193125-26-321442SEC ↗ 4 Jun 9, 2026 Period Jun 5, 2026 0001193125-26-263997SEC ↗ 4 Jun 8, 2026 Period Jun 4, 2026 0001193125-26-262067SEC ↗ 8-K Jun 4, 2026 Period Jun 3, 2026 0001628280-26-040784SEC ↗ Form 4 Insider activity Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
“Insider purchase” rule Code P · non-derivative · acquired · direct ownership · positive price and shares · not amended
Inspectable by design
Every displayed number has a lineage. GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗